ResearcherLeibniz-Forschungsinstitut für Molekulare PharmakologieActive in the last 2 years

Marc Nazaré

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-1602-2330; OpenAlex author ID A5049855471. Sources: OpenAlex.

Their work

Papers: 1 (first author 0, last author 1)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 4

Papers, trials and grants by year

2024: 1 paper

Papers 1

DOTA-Based Plectin-1 Targeted Contrast Agent Enables Detection of Pancreatic Cancer in Human Tissue. Last author DOI 10.1002/anie.202318485 ↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Marina Lesina · 1 shared paper, 2024 · strength 0.19
- Paper DOTA-Based Plectin-1 Targeted Contrast Agent Enables Detection of Pancreatic Cancer in Human Tissue. DOI 10.1002/anie.202318485 ↗
Thais Gazzi · 1 shared paper, 2024 · strength 0.19
- Paper DOTA-Based Plectin-1 Targeted Contrast Agent Enables Detection of Pancreatic Cancer in Human Tissue. DOI 10.1002/anie.202318485 ↗
İhsan Ekin Demir · 1 shared paper, 2024 · strength 0.19
- Paper DOTA-Based Plectin-1 Targeted Contrast Agent Enables Detection of Pancreatic Cancer in Human Tissue. DOI 10.1002/anie.202318485 ↗
Hana Algül · 1 shared paper, 2024 · strength 0.19
- Paper DOTA-Based Plectin-1 Targeted Contrast Agent Enables Detection of Pancreatic Cancer in Human Tissue. DOI 10.1002/anie.202318485 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.